Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study

Avelumab first-line maintenance (1LM) is approved for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who do not have disease progression after platinum-based chemotherapy (PBC). This retrospective study describes real-world treatment patterns and clinical outcomes in pati...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sneha Sura, Manojkumar Bupathi, Valerie Morris, Paul Conkling, Karen Todoroff, Abhijeet Bhanegaonkar, Chiemeka Ike
Format:	Article
Language:	English
Published:	MDPI AG 2025-03-01
Series:	Current Oncology
Subjects:	avelumab first-line maintenance locally advanced or metastatic urothelial cancer overall survival real-world time to next treatment real-world time to treatment discontinuation
Online Access:	https://www.mdpi.com/1718-7729/32/4/187
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study

Similar Items